Clinical Trial Update: A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain [Phase 2]

View source ↗

Summary

Acalabrutinib is being studied in combination with R-CHOP for previously untreated mantle cell lymphoma in Spain in a Phase 2 trial that is currently enrolling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: AstraZeneca | Conditions: Mantle-cell Lymphoma | Phase 2 | Status: RECRUITING